| INTRODUCTION
Prostate cancer (PCa) is a leading cause of cancer death in American men. 1 The standard treatment for metastatic PCa is androgen deprivation therapy (ADT). While the majority of patients respond to ADT, most tumors will eventually progress to incurable castration resistant PCa (CRPC). 2 Current approaches to manage CRPC include next-generation ADT, such as enzalutamide and abiraterone, as well as docetaxel, targeted radiotherapeutics, and immunotherapies. 3 There is a critical need to consider additional therapeutic targets, and therapeutic compounds, which may provide alternative mechanisms for CRPC management. The pterocarpanquinone, LQB-118, is a synthetic compound capable of inducing apoptosis in leukemia cell lines and leukemic samples from patients. 4 ,5 LQB-118 demonstrated low cytotoxicity toward human peripheral blood mononuclear cells from healthy donors, as well as in Swiss webster mice. 6, 7 Initial studies of LQB-118 in PCa cell models have been positive, where treatment induced significant cytotoxicity and apoptosis in the androgenindependent PCa cell model, PC3. Treatment was associated with cell cycle arrest, decreased expression of c-Myc, cyclin D1 and cyclin B1 mRNA, and up-regulation of the cell cycle inhibitor p21. 8 The mechanisms of LQB-118 activation and cytotoxicity have yet to be fully elucidated. It has been suggested that LQB-118, with a structure-related to naphthoquinone, might be reduced by the NQO1 enzyme. 9 Naphthoquinone reduction can generate elevated intracellular levels of ROS, causing significant redox stress. 9 A variety of drugs exert their anti-cancer function through increasing ROS production. 10 Nonetheless, some tumor cells can overcome drug-induced oxidative stress through the over-expression of redox-active factors such as nuclear factor erythroid-2 related factor 2 (Nrf2), superoxide dismutase (SOD), and glutathione peroxidase (GPx). 11, 12 This rapid adjustment to altered redox environments, so called "Redox Resetting," can provide additional mechanisms toward therapeutic resistance. 13 Here we provide new analyses of LQB-118 therapy in PCa cell and tumor models, and we characterize mechanisms of drug activation, activity, and resistance. Our results correlate LQB-118 activity with quinone reduction, induced NQO1 expression, and ROS generation.
LQB-118 treatment induced the redox responsive genes Nrf2 and SOD1, and transient knock-down of SOD1 through siRNA or miRNA caused an increase in PCa cell sensitivity to LQB-118. Oral LQB-118 therapy safely and effectively attenuated the growth of established PCa tumors, in vivo, in athymic nude mouse xenograft models. These results provide further support for LQB-118 as a potential anti-cancer therapeutic, and they offer new insights into the mechanisms of LQB-118 activity in human cancer cells.
2 | METHODS
| Cell lines
Androgen-dependent (LAPC4 and LNCaP) and androgen-independent (PC3) human PCa cells were cultured as follows: LNCaP and PC3 in RPMI 1640 media, and LAPC4 in IMDM plus 1 nM R1881, each supplemented with 10% fetal bovine serum and 5 μM ciprofloxacin or 100 mg/L penicilin and 70 mg/L streptomycin. Cells were maintained at 37°C in a 5% CO 2 humidified atmosphere. All cell lines were authenticated by the DNA Diagnostics Center (Farifield, OH) or BCRJ (Rio de Janeiro, RJ, Brazil) and confirmed mycoplasma free.
| Chemicals and reagents
The pterocarpanquinone LQB-118 was synthesized in the Bioorganic Chemistry Laboratory, NPPN, Federal University of Rio de Janeiro (Brazil), as described elsewhere, 6 and was kindly donated by Dr. Chaquip Netto and Dr. Paulo Costa. 3,3′-metileno-bis(4-hydroxycoumarin) (Dicumarol), N-acetylcystein (NAC) was purchased from
Sigma. All compounds were dissolved in 100% DMSO (Merck, Germany), except for NAC, dissolved in culture medium. Maximal DMSO concentration in culture was 0.1%, without cytotoxic effects.
For in vivo experiments, LQB-118 was diluted in 15% ethanol containing 1.5% Tween 20. Anti-human SOD1 (SAB1409700) and anti-human ACTB (AC-15) were purchased from Sigma-Aldrich (St.
Louis, MO). SiRNA FlexiTube GeneSolution (GS6647) was purchased from Qiagen (Germantown, MD) and miRNA mimics were purchased from Dharmacon GE (Lafayette, CO).
| Cytotoxicity assays
After adhesion in 96 flat-bottom-well microplates, cells (2 × 10 4 cells/ mL) were incubated in the absence (control) or presence of different LQB-118 concentrations at 37°C in a 5% CO 2 humidified atmosphere, to calculate the concentration of LQB-118 that inhibits 50% of relative cell viability (IC50). Cells were either pretreated or not for 2 h with NAC (5 mM) followed by treatment with LQB-118 at concentrations equal to or moderately lower than the determined IC50 (Table 1) and/ or Dicoumarol (50 μM) for 12 h. Cells were also transfected or without siRNA or miRNA mimics, after 48 h, cell lines were seeded and treated or not with LQB-118 for an additional 12 h. Cell survival/cytotoxicity was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium, Sigma Chemical Co.) assay after 12 h by incubation at 37°C (last 2 h of culture) with 10 µL/well of 5 mg/mL MTT stock solution.
14 Afterwards, 100 µL/well of SDS 10% solution, containing in mRNA levels were calculated by the 2 −ΔΔCt method. 16 All data were normalized using as reference the GAPDH mRNA levels. Each PCR efficiency was evaluated by standard curve and primers specificity were checked by melting curve analysis. The primer sequences were as follows: Nrf2 5′-TGCCAACTACTCCCAGGTT-3′ and 5′-CAAACGG-GAAATGTCTGCG-3′; NQO1 5′-AAGGATGGAAGAAACGCCTG-GAGA-3′ and 5′-GGCCCACAGAAAGGCCAAATTTCT-3′; SOD1 5′-TGGCCGATGTGTCTATTGAA-3′ and 5′-CACCTTTGCCCAAGTCATC T-3′; CAT 5′-GCCATTGCCACAGGAAAGTA-3′ and 5′-CCTTGGTGA-GATCGAATGGA-3′; GPx 5′-GGTTCGAGCCCAACTTCATG-3′ and 5′-GGAGACCAGGTGATGAGCTT-3′.
| miRNA target prediction analysis
MicroRNAs target prediction for SOD1 was determined by TargetScan and Tarbase and candidates were considered with miRSVR scores equal to or below than −0.5, and miTG scores equal or higher than 0.5.
17,18
2.9 | siRNA and miRNA sensitivity analysis reporter activity was assessed using a dual luciferase enzyme assay as previously described. 19, 20 Firefly luciferase signal was normalized to the internal control Renilla luciferase. 
| In vivo assay: Tumor xenograft studies

| Statistical analysis
The results are reported as mean ± standard deviation (SD) of at least three independent experiments. Significant differences between pairs of groups were accessed using Student's t-test, with a significance level set at P < 0. Figure 2C ). These results implicate quinone reduction and ROS generation as mechanisms of LQB-118 activation and cytotoxicity.
| LQB-118 treatment induces Nrf2 and SOD1 gene expression
To investigate the possible responses to LQB-118-induced ROS generation, the expression of cellular catalase, glutathione peroxidase (GPx), Nrf2, and SOD1 were quantified in PC3 cells (Figure 3 ). 
| SOD1 induction is protective against LQB-118 cellular cytotoxicity
Expanding upon LQB-118 cytotoxicity and ROS production in PC3 cells, we evaluated treatment responses in additional PCa cell lines. Specifically, in LNCaP cells, miR-206 decreased SOD1 levels by 7.7% (P < 0.05), miR-1 decreased SOD1 levels by 38.4% (P < 0.01), and miR-101 reduced SOD1 levels by 44.2% (P < 0.01) ( Figure 6C ). In LAPC4 cells (Figure 6D ), miR-206 reduced SOD1 protein expression by 67.6% (P < 0.001), miR-1 decreased SOD1 levels by 92.3% (P < 0.001),
and miR-101 down-regulated SOD1 levels by 64.1% (P < 0.01).
Therefore, only miR-101 was capable of targeted SOD1 reduction in all three cell lines.
Each miRNA mimic was then transfected into PCa cells to determine their influence on cell sensitivity to LQB-118. Surprisingly, in PC3 cells, none of the miRNAs demonstrated enhanced LQB-118 sensitivity, when compared to the control miRNA, including miR-101
( Figure 7A ). However, miRNA-101 was able to enhance LQB-118-induced cytotoxicity in LNCaP ( Figure 7B ) and LAPC4 cells ( Figure 7C ), when compared to control mimic transfected cells (P < 0.05).
Interestingly, the other SOD1-targeting miRNAs had mixed effects on LQB-118 treatment potency. These results may be due to the ability of each miRNA to target multiple gene transcripts, when compared to siRNAs, which are designed to target only a single gene. cytotoxicity is at least partially dependent upon cellular quinone reduction capability. This activity is associated with the induced expression of NQO1, a well-characterized quinone reductase. 22 Among intracellular quinone metabolism enzymes, NQO1 has emerged as a promising target for cancer therapy because of its elevated expression in most solid tumors. 23, 24 The association between cytotoxicity and increased NQO1 expression has been described for other naphthoquinones in many types of cancer cells. 22, 23, 25, 26 In general, naphthoquinone is reduced to an unstable hydroquinone or semiquinone, which rapidly undergoes one or two-steps of oxidation to return to the parental form, perpetuating a futile redox cycle and resulting in the generation of ROS, mainly O Results show mean ± SD of three independent experiments. *P < 0.05 and **P < 0.01 and ***P < 0.001, relative to transfected cells with the respective miRNA, and # P < 0.05, relative to LQB-118 treated, but non-transfected cells (Student's t-test) cytotoxicity was markedly reduced by the free radical scavenger NAC, SOD1 is a key regulator of ROS homeostasis in cancer cells and its elevated expression may contribute to pathways of proliferation and survival. 33 In light of this, SOD1 has been considered to be a potential therapeutic target for cancer. 34 Since LQB-118 treatment resulted in induced SOD1 protein expression levels, we considered whether SOD1 expression could drive resistance to LQB-118-induced cell death and apoptosis. Indeed, loss of SOD1 expression by siRNA knockdown significantly increased PCa cell sensitivity to LQB-118, indicating that SOD1 is a key regulator of cellular response and resistance to LQB-118 cytotoxicity. We further sought a physiological strategy to suppress SOD1 activity in PCa cells and found that SOD1 was a possible target of miR-206, miR-1, and miR-101, three miRNAs with frequently decreased expression in PCa. 35 All three miRNAs were confirmed to target and suppress SOD1 protein expression and SOD1 3′UTR reporter activity. However, the potency of each miRNA to target SOD1 and to enhance LQB-118 sensitivity varied significantly between cell lines. In general, miRNA-mediated gene regulation is consistent among different cell types. However, there is potential for altered miRNA targeting landscapes due to differences in gene expression or usage of alternative 3′UTR isoforms. 36 Nonetheless, miR-101 consistently reduced SOD1 protein expression in all three PCa cell lines and enhanced LQB-118 cytotoxicity in two of three PCa cell lines. In addition to SOD1, miR-101 has been reported to suppress EZH2 and FOXM1, two drivers of PCa cell viability, proliferation, migration, and invasion. 37, 38 Previous studies have demonstrated the promise of LQB-118 as a therapeutic agent in PCa cells. 8 Our data further establish LQB-118 activity in multiple PCa cell models. Here, for the first time, we also demonstrate the anti-cancer activity of LQB-118 in vivo, following oral administration (10 mg/kg). Treatment with LQB-118 at this dose appeared to have no measurable adverse effects, which are consistent with previous promising pre-clinical toxicological studies, even at doses ten times higher than the therapeutic dose. 19 Further studies are needed to evaluate the anti-cancer potential of LQB-118 at higher doses, while 
